AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.

被引：0

作者：

Casasnovas, Rene-Olivier

Meignan, Michel

Reman, Oumedaly

Gaillard, Isabelle

Stamatoullas, Aspasia

Brice, Pauline

Salles, Gilles A.

Bouabdallah, Reda

Bologna, Serge

Nicolas-Virelizier, Emmanuelle

Morschhauser, Franck

Janvier, Maud

Andre, Marc

Berriolo-Riedinger, Alina

Traverse-Glehen, Alexandra

Edeline, Veronique

Dartigues, Peggy

Parrens, Marie

Mounier, Nicolas

Ferme, Christophe

机构：

[1] Hop Le Bocage, Dijon, France

[2] Hop Henri Mondor, F-94010 Creteil, France

[3] CHU Caen, F-14000 Caen, France

[4] Ctr Henri Becquerel, F-76038 Rouen, France

[5] Hosp St Louis, Paris, France

[6] Ctr Hosp Lyon Sud, Oullins, France

[7] Inst J Paoli I Calmettes, F-13009 Marseille, France

[8] Ctr Hosp Univ, Nancy, France

[9] Ctr Leon Berard, F-69373 Lyon, France

[10] Hop Claude Huriez, Lille, France

[11] Inst Curie, Paris, France

[12] Ctr Hosp Univ Mt Godinne, Dinant, Belgium

[13] Ctr Georges Francois Leclerc, Dijon, France

[14] Hop Lyon Sud, Hosp Civils Lyon, Pierre Benite, France

[15] Inst Gustave Roussy, Villejuif, France

[16] Ctr Hosp Univ, Bordeaux, France

[17] Ctr Hosp Univ Archet, Nice, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8615

引用

页数：1

共 50 条

[21] A randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX.
Cartwright, Thomas H.
Cohn, Allen Lee
Richards, Donald A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[22] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, randomized, phase II study.
Lee, Kyung-ha
Kim, Ji Yeon
Yang, In Jun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS230 - TPS230
[23] Treatment related organ toxicities at one year follow-up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group
Ferdinandus, J.
Moccia, A.
Greil, R.
Hertzberg, M.
Schaub, V
Huttmann, A.
Keil, F.
Dierlamm, J.
Haenel, M.
Novak, U.
Meissner, J.
Zimmermann, A.
Mathas, S.
Zijlstra, J.
Fossa, A.
Viardot, A.
Hertenstein, B.
Martin, S.
Giri, P.
Kamper, P.
Molin, D.
Kreissl, S.
Fuchs, M.
Behringer, K.
Schneider, G.
Rosenwald, A.
Klapper, W.
Eich, H. -T
Baues, C.
Hallek, M.
Dietlein, M.
Kobe, C.
Diehl, V
Engert, A.
Borchmann, P.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 111 - 111
[24] Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study).
Hagenbeek, A
Carde, P
Noordijk, E
Thomas, J
Tirelli, U
Monconduit, M
Eghbali, H
Mandard, AM
HenryAmar, M
BLOOD, 1997, 90 (10) : 2603 - 2603
[25] Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study
Zhao, Hongqin
Li, Lili
Su, Huafang
Lin, Baochai
Zhang, Xuebang
Xue, Shengliu
Fei, Zhenghua
Zhao, Lihao
Pan, Qintuo
Jin, Xiance
Xie, Congying
ONCOTARGET, 2016, 7 (43) : 70969 - 70978
[26] MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION IN HIGH-RISK HODGKIN LYMPHOMA (HL) PATIENTS, WITH A POSITIVE FDG-PET SCAN AFTER TWO ABVD COURSES - GITIL HD0607 STUDY
Gallamini, A.
Tarella, C.
Patti, C.
Gianni, A.
Bolis, S.
Trentin, L.
Biggi, A.
Chauvie, S.
Mennitto, M.
Rambaldi, A.
ANNALS OF ONCOLOGY, 2011, 22 : 139 - 139
[27] A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Parikh, Sameer A.
Muchtar, Eli
Laplant, Betsy
Ding, Wei
Ailawadhi, Sikander
Koehler, Amber
Call, Timothy G.
Kenderian, Saad S.
Leis, Jose F.
Fonder, Amie
Shi, Min
Chanan-Khan, Asher A.
Pettinger, Adam
Witzig, Thomas E.
Thompson, Carrie A.
Villasboas, Jose C.
Sholes, Jessica M.
Hanson, Curtis A.
Braggio, Esteban
Medina, Kay L.
Slager, Susan L.
Kay, Neil E.
BLOOD, 2019, 134
[28] Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer - A randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, G
Zisiadis, A
Dafni, U
Konstantaras, C
Hatzitheoharis, G
Papavramidis, S
Bousoulegas, A
Basdanis, G
Giannoulis, E
Dokmetzioglou, J
Katsohis, C
Nenopoulou, E
Karvounis, N
Briassoulis, E
Aravantinos, G
Kosmidis, P
Skarlos, D
Pavlidis, N
ONCOLOGY, 2000, 58 (03) : 227 - 236
[29] A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
Schneeweiss, Andreas
Moebus, Volker
Blohmer, Jens Uwe
Costa, Serban Dan
Denkert, Carsten
Eidtmann, Holger
Hanusch, Claus
Hilfrich, Joern
Huober, Jens Bodo
Jackisch, Christian
Paepke, Stefan
Kuemmel, Sherko
Tesch, Hans
Untch, Michael
Loibl, Sibylle
Von Minckwitz, Gunter
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[30] PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup
Fornecker, Luc-Matthieu
Lazarovici, Julien
Aurer, Igor
Casasnovas, Rene-Olivier
Gac, Anne-Claire
Bonnet, Christophe
Bouabdallah, Krimo
Perrot, Aurore
Specht, Lena
Touati, Mohamed
Eisenmann, Jean Claude
Borel, Cecile
Stamatoullas, Aspasia
Nicolas-Virelizier, Emmanuelle
Pascal, Laurent
Lugtenburg, Pieternella
Bellei, Monica
Traverse-Glehen, Alexandra
Copie, Christiane
Hutchings, Martin
Versari, Annibale
Meignan, Michel
Federico, Massimo
Andre, Marc
BLOOD, 2017, 130

← 1 2 3 4 5 →